** U.S.-listed shares of China-based drug developer Zai Lab ZLAB.O fall 6% to $28.11 after the bell
** ZLAB commences public offering of $200 mln of American depositary shares
** Company plans to use the proceeds for general corporate purposes
** ZLAB has 98 mln outstanding shares, with a capitalization of $3 bln market, according to data compiled by LSEG
** Goldman Sachs, Jefferies and Leerink Partners are the joint book-running managers for the offering
** As of last close, ZLAB shares up 9.6% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。